Developer docs
API playgroundTry for free, no card

Search company profiles

10x Genomics, Inc.

Full company profile

uuid00ypqyj

Namestring
10x Genomics, Inc.
Legal namestring
10x Genomics, Inc.
Websiteurl
10xgenomics.com
Company typeenum
Public
Founded yearint
2016
Short descriptiontext

10x Genomics develops single cell and spatial multiomics instruments, assays, and software for biological research. The publicly traded company sells Chromium, Atera, Xenium, Visium, and Flex platforms to academic, biopharmaceutical, clinical, and computational biology customers globally.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1,001–5,000
akta.pro rankint
HeadquartersPleasanton, United States
HQ citystring
Pleasanton
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
single cell analysis, spatial biology, genomics instruments, multiomics assays, cell sequencing
Industry4 codes
PRIMARYHLAGAIAF
Molecular Biology & Genomics Instruments (PCR/qPCR, Sequencing, Microarrays)
SECONDARYHLAAAIAF
Single-Cell & Spatial Omics Discovery Platforms (target ID/validation, functional profiling)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAALAL
Multiplex & High-Throughput Diagnostics Platforms (microarrays, digital PCR, lab automation-enabled assays)
SECONDARYHLAFAMAE
Molecular Diagnostics & Genomics Laboratories
NAICS code2 codes
  • Analytical Laboratory Instrument Manufacturing334516
  • Navigational, Measuring, Electromedical, and Control Instruments Manufacturing3345
SIC code2 codes
  • Laboratory Analytical Instruments3826
  • In Vitro & In Vivo Diagnostic Substances2835
Product category
Single Cell and Spatial Biology Instruments
Social media profiles1 record
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model4 records
1Instrument Sales
TypeHardware Sales
Description

Sale of capital equipment including Chromium X Series instruments, Atera, Xenium Analyzer, and Visium CytAssist. Instrument revenue declined 36% in Q4 2025 and 39% for full year 2025, reflecting challenging capital equipment funding environment.

seekingalpha.com
2Consumables and Reagents
TypeSubscription Recurring
Description

Recurring revenue from reagents, kits, and consumables for single cell and spatial biology assays. Consumables revenue grew 6% in Q4 2025 and 3% for full year 2025, representing the majority of product revenue.

seekingalpha.com
3Services
TypeProfessional Services
Description

Service revenue from sample processing and research services. Services revenue showed strong growth with 48% increase in Q3 2025.

prnewswire.com
4Software and Cloud Analysis
TypeSubscription Recurring
Description

Cloud-based data analysis platform providing software-as-a-service capabilities for processing 10x Genomics data

10xgenomics.com
Marketing channels7 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels5 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Marketing or Sales, Supply Chain, Operations
Pricing details3 tiers
1Enterprise instruments (Chromium X Series, Atera, Xenium Analyzer, Visium CytAssist)
ModelOne time/ perpetual licenseBilling cadenceMulti-year contract
Notes

Capital equipment pricing provided via sales quote requests. Chromium Xo available at new low price point. Atera and Xenium represent premium instruments.

10xgenomics.com
2Atera Catalyst Research Services
ModelUsage-basedBilling cadencePay-as-you-go
Notes

Limited-time offering to provide whole transcriptome single cell spatial access to researchers while awaiting instrument delivery

10xgenomics.com
3Reagents, kits, and consumables
ModelUnit PricingBilling cadencePay-as-you-go
Notes

Available through company store with account-based pricing. Flex Apex kit and other assay reagents offered at per-unit pricing.

10xgenomics.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 5 records shown
1Atera
Description

In situ spatial biology platform for whole-transcriptome spatial analysis at unprecedented scale with single-cell sensitivity.

10xgenomics.com
+4 more records
Core offering1 text field

10x Genomics develops and sells single cell and spatial multiomics platforms comprising capital instruments (Chromium, Atera, Xenium, Visium CytAssist), proprietary consumables and reagent kits, and analysis software (Cell Ranger, Cloud Analysis, Loupe Browser). Its products profile individual cells, detect rare populations, map spatial gene expression in tissues, and generate multiomic datasets for academic, translational, biopharmaceutical, and clinical research customers.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • Up to 80% cell recovery efficiency with GEM-X chemistry
+4 more records
Product and service6 records
1Chromium Single Cell
CategorySingle Cell Analysis Platform
Description

Droplet-based single cell multiomics platform for profiling gene expression, immune repertoire, chromatin accessibility, and multiomic features across thousands of samples and billions of cells, including from FFPE tissue.

2Atera In Situ
CategorySpatial Biology Platform
Description

Scalable in situ spatial biology platform providing whole-transcriptome coverage at single-cell sensitivity, enabling high-throughput spatial gene expression analysis on intact tissue.

3Xenium In Situ
CategorySpatial Imaging Platform
Description

High-plex in situ imaging platform for subcellular profiling of RNA targets from fresh frozen or FFPE tissues, integrating high-resolution imaging with onboard data analysis.

4Visium Spatial
CategorySpatial Gene Expression Platform
Description

NGS-based spatial gene expression platform providing whole-transcriptome spatial analysis at single-cell scale, with CytAssist-enabled workflow for FFPE and fresh frozen tissue samples.

5Flex / Flex Apex
CategorySingle Cell Assay / Consumable
Description

Plate-based multiplexing single cell assay (Flex Apex) for profiling FFPE and fixed whole blood samples using Chromium Precision chemistry, with massive-throughput plate-based workflows.

6Cell Ranger & Analysis Software
CategoryBioinformatics Software
Description

Suite of free and cloud-based analysis pipelines, including Cell Ranger for data processing, Cloud Analysis for hosted analysis, and Loupe Browser for visualization, supporting 10x Genomics single cell and spatial data.

Scale indicator8 records

Each record includes

Type, Value, Description, Source

Partnership24 partners
Strategic tierStrategicTypeTechnology or IntegrationAnnounced on2026-06-29
Description

Collaboration supporting Roche's AXELIOS 1 next-generation sequencing platform launch, with 10x Genomics providing technology integration for data analysis capabilities. Positions 10x in sequencing market valued at USD 7.3 billion.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-06-17
Description

Multi-year research collaboration to analyze advanced bladder cancer tumor samples using Flex Apex, Xenium, and Atera spatial biology platforms to identify biomarkers predicting patient response to antibody-drug conjugate treatments. Study will examine tumor samples from patients undergoing ADC and immunotherapy treatments, generating comprehensive multimodal datasets linking single cell and spatial profiles with clinical outcomes.

3Proteintech Genomics
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2026-06-09
Description

Acquisition of Proteintech Genomics, a division within Proteintech Group, expanding 10x's proteomics capabilities in single cell and spatial biology. The acquisition brings the Human Discovery Panel, the largest antibody-based single cell protein panel, designed to support integrated analysis of intracellular proteins, cell surface proteins, and transcriptomic profiles within sequencing-compatible workflows.

prnewswire.com
Strategic tierStrategicTypeTechnology or IntegrationAnnounced on2026-04-18
Description

Atera early access partner that generated data demonstrating platform's capabilities, including identification of rare immune cell populations and mapping of tumor microenvironments.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-03-25
Description

STELA (Spatial Tissue Embedding Learning Atlas) initiative anchored by 10x Genomics' Xenium platform, aiming to profile up to 100,000 patient tissue specimens across three continents (~20-fold increase over existing atlases). Serves as data backbone for M-Optimus multimodal world model of biology. Commercial expansion to Atera planned for 2027.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-03-25
Description

Strategic partner in STELA initiative contributing high-throughput laboratory workflows for generating harmonized multi-omics patient data across the 100,000-specimen atlas.

Strategic tierStrategicTypeStrategic or Co-development PartnerAnnounced on2026-03-17
Description

Collaboration producing world's largest in vivo CRISPR atlas with 8 million brain-wide cells using Perturb-seq technology. 10x Genomics provided technology for generating the largest known causal genomics resource in living tissue for drug discovery and AI model training.

Strategic tierStrategicTypeStrategic or Co-development PartnerAnnounced on2026-03-17
Description

Collaboration partner in PerturbAI's 8M cell CRISPR atlas project, contributing to world's largest in vivo causal genomics resource for mouse brain research.

Strategic tierStrategicTypeTechnology or IntegrationAnnounced on2026-03-17
Description

Technology partner providing accelerated computing infrastructure for PerturbAI's in vivo CRISPR atlas project and causal AI model development.

Strategic tierStrategicTypeStrategic or Co-development PartnerAnnounced on2026-02-26
Description

Partner in CRI Discovery Engine initiative alongside 10x Genomics, Stanford University, Penn Medicine, and Memorial Sloan Kettering to standardize and pool cancer immunotherapy research for AI-driven breakthroughs.

Strategic tierStrategicTypeStrategic or Co-development PartnerAnnounced on2026-02-26
Description

Partner in CRI Discovery Engine initiative to create shared data infrastructure for cancer immunotherapy research enabled by 10x platforms.

Strategic tierStrategicTypeStrategic or Co-development PartnerAnnounced on2026-02-26
Description

Partner in CRI Discovery Engine initiative to standardize cancer immunotherapy research data infrastructure with 10x Genomics spatial and single cell platforms.

13PharosAI
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-02-04
Description

UK research consortium backed by £18.9 million government funding using Xenium spatial platform to build one of world's largest multimodal cancer datasets. Initiative will transform archived NHS cancer samples into high-resolution AI-ready datasets, initially focusing on breast cancer before expanding to lung and pancreatic cancer through 2027.

prnewswire.com
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-01-12
Description

Multi-year collaboration analyzing tumor samples from hundreds of patients with major solid cancer types using Chromium Flex single cell assay and Xenium spatial platform. Research aims to identify biomarkers and develop clinical reporting framework for precision oncology treatments including ADCs, radioligand therapies, and bispecific antibodies.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-01-12
Description

Collaboration analyzing peripheral blood samples from 1,000 patients with rheumatoid arthritis, systemic lupus erythematosus, and giant cell arteritis using Chromium Flex single-cell assay. Research aims to identify immune signatures associated with disease activity, flare, remission, and therapeutic response.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-01-12
Description

AI-driven immuno-oncology initiative involving over 20,000 samples to build comprehensive dataset for future cancer treatments and vaccines using high-resolution biological data from 10x platforms.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-01-07
Description

ImmuneScape multiomics research initiative leveraging Xenium spatial and Chromium Flex platforms to study transplant organ rejection at cellular resolution. Program will generate high-resolution maps of immune mechanisms underlying antibody-mediated rejection and microvascular inflammation to support future clinical diagnostic development.

Strategic tierStrategicTypeTechnology or IntegrationAnnounced on2025-10-20
Description

Integration of Anthropic's Claude for Life Sciences AI platform with 10x Genomics' single cell and spatial biology analysis platforms. Enables researchers to access, analyze, and interpret biological datasets through cloud-based interfaces for automated QC, gene/protein interaction analyses, and multi-step workflows.

Strategic tierStrategicTypeTechnology or IntegrationAnnounced on2023-01-01
Description

Collaboration since 2023 to automate single cell gene expression workflows, enabling processing capacity increase to 96 samples per day vs 24 with manual methods, reducing hands-on time from over 5 hours to 1 hour.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Virtual Cell Atlas initiative using Flex platform to generate 300M+ cell CRISPR perturbational dataset to fuel AI cell models that predict cellular responses and accelerate therapeutic target discovery.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Billion Cells Project using Chromium technology for landmark single cell dataset to deepen understanding of cellular behavior and gene function (1B cells).

Strategic tierStrategicTypeStrategic or Co-development Partner
Description

MOSAIC (Multi-Omics Spatial Atlas In Cancer) initiative using Visium and Flex technologies for massive pan-cancer spatial transcriptomics dataset (7,000 FFPE tissues) to enable AI-based therapeutic prediction modeling.

Strategic tierStrategicTypeStrategic or Co-development Partner
Description

X-Atlas/Orion initiative using Universal 5' platform for largest publicly available Perturb-seq atlas targeting all human protein-coding genes for foundational model training (8M cells).

Strategic tierStrategicTypeTechnology or Integration
Description

Partnership combining 10x Genomics single cell and spatial sequencing quality with Ultima's ultra-low-cost sequencing capacity to unlock biological insights at large scales.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Direct competitor in single-cell RNA sequencing with an instrument-free, combinatorial barcoding chemistry (Evercode). Targets the same academic and translational single-cell market as Chromium with a different deployment model.

TypeBroad incumbent
Description

Broad incumbent with the BD FACSDiscover S8 sorter combining spectral flow cytometry with imaging, plus cell sorting and single-cell genomics reagents. Competes for single-cell biology budgets across pharma and academic customers.

TypeDirect peer
Description

Direct peer in single-cell biology through mass cytometry (CyTOF/Hyperion imaging mass cytometry) and microfluidics-based single-cell workflows, competing for similar translational and immunology research customers.

TypeBroad incumbent
Description

Long-read sequencing incumbent (Revio, Onso) increasingly bundled with single-cell workflows through partnerships with 10x-compatible kit providers; competes for translational genomics research budgets.

TypeDirect peer
Description

Single-cell transcriptomics competitor offering the Microwell-seq-based Singleron Matrix and AccuraSCOPE platforms, particularly active in Asia-Pacific translational and clinical research markets overlapping with 10x.

TypeBroad incumbent
Description

Dominant next-generation sequencing incumbent whose platforms underpin 10x's NGS-based assays (Visium, Chromium); also develops connected-annotation and single-cell partnerships that compete with 10x-enabled workflows.

TypeBroad incumbent
Description

Broad life science tools incumbent offering ddPCR, single-cell ATAC-seq (ATAC-Seq), and ZE5 cell analyzers, with overlapping presence in genomics and cell biology research labs that purchase 10x instruments.

TypeDirect peer
Description

Direct competitor in high-plex spatial biology through the CODEX/PhenoCycler platform, overlapping with Xenium in tissue imaging and multiplexed spatial phenotyping for translational research.

TypeEmerging player
Description

Emerging sequencing platform (AVITI) pursuing cost-competitive short-read sequencing; competes for benchtop NGS budgets where 10x's Visium and Chromium workflows are deployed, with potential partnership overlap.

TypeDirect peer
Description

Direct competitor in spatial transcriptomics via the CosMx SMI platform and GeoMx Digital Spatial Profiler. Most head-to-head rival to 10x's Xenium and Atera in the in situ spatial biology market.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers10 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile5 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability6 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles5 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

10x Genomics, Inc.

Single Cell and Spatial Biology Instruments10xgenomics.com

10x Genomics develops single cell and spatial multiomics instruments, assays, and software for biological research. The publicly traded company sells Chromium, Atera, Xenium, Visium, and Flex platforms to academic, biopharmaceutical, clinical, and computational biology customers globally.

10x Genomics, Inc. firmographics

Firmographics
Name
10x Genomics, Inc.
Legal name
10x Genomics, Inc.
Website
https://10xgenomics.com
Company type
Public
Founded year
2016
Operating status
Operating
Headcount range
1,001–5,000 employees
Short description
10x Genomics develops single cell and spatial multiomics instruments, assays, and software for biological research. The publicly traded company sells Chromium, Atera, Xenium, Visium, and Flex platforms to academic, biopharmaceutical, clinical, and computational biology customers globally.
Ownership category
akta.pro rank

10x Genomics, Inc. industry classification

Industry
Product category
Single Cell and Spatial Biology Instruments
NAICS
Analytical Laboratory Instrument Manufacturing (334516), Navigational, Measuring, Electromedical, and Control Instruments Manufacturing (3345)
SIC
Laboratory Analytical Instruments (3826), In Vitro & In Vivo Diagnostic Substances (2835)
akta.pro industry
PRIMARYHLAGAIAF
Molecular Biology & Genomics Instruments (PCR/qPCR, Sequencing, Microarrays)
SECONDARYHLAAAIAF
Single-Cell & Spatial Omics Discovery Platforms (target ID/validation, functional profiling)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAALAL
Multiplex & High-Throughput Diagnostics Platforms (microarrays, digital PCR, lab automation-enabled assays)
SECONDARYHLAFAMAE
Molecular Diagnostics & Genomics Laboratories

Keywords

  • Single cell analysis
  • Spatial biology
  • Genomics instruments
  • Multiomics assays
  • Cell sequencing

Where 10x Genomics, Inc. is headquartered

Location

Headquarters

HQ city
Pleasanton
HQ country
United States
HQ region
North America

Offices1 record

Markets served

10x Genomics, Inc. business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Marketing or Sales, Supply Chain, Operations

Revenue model

  1. Instrument Sales: Sale of capital equipment including Chromium X Series instruments, Atera, Xenium Analyzer, and Visium CytAssist. Instrument revenue declined 36% in Q4 2025 and 39% for full year 2025, reflecting challenging capital equipment funding environment.
  2. Consumables and Reagents: Recurring revenue from reagents, kits, and consumables for single cell and spatial biology assays. Consumables revenue grew 6% in Q4 2025 and 3% for full year 2025, representing the majority of product revenue.
  3. Services: Service revenue from sample processing and research services. Services revenue showed strong growth with 48% increase in Q3 2025.
  4. Software and Cloud Analysis: Cloud-based data analysis platform providing software-as-a-service capabilities for processing 10x Genomics data

Pricing tiers

ModelBillingPrice
One time/ perpetual licenseMulti-year contractEnterprise instruments (Chromium X Series, Atera, Xenium Analyzer, Visium CytAssist)
Usage-basedPay-as-you-goAtera Catalyst Research Services
Unit PricingPay-as-you-goReagents, kits, and consumables

Go-to-market motion2 records

Distribution channels5 records

Marketing channels7 records

10x Genomics, Inc. product offering

Product offering

Core offering

10x Genomics develops and sells single cell and spatial multiomics platforms comprising capital instruments (Chromium, Atera, Xenium, Visium CytAssist), proprietary consumables and reagent kits, and analysis software (Cell Ranger, Cloud Analysis, Loupe Browser). Its products profile individual cells, detect rare populations, map spatial gene expression in tissues, and generate multiomic datasets for academic, translational, biopharmaceutical, and clinical research customers.

Differentiator

Problem solved

Functional benefit

Brands

  • Atera: In situ spatial biology platform for whole-transcriptome spatial analysis at unprecedented scale with single-cell sensitivity.
  • Chromium
  • Xenium
  • Visium
  • Flex

Products and services

  • Chromium Single Cell Droplet-based single cell multiomics platform for profiling gene expression, immune repertoire, chromatin accessibility, and multiomic features across thousands of samples and billions of cells, including from FFPE tissue.
  • Atera In Situ Scalable in situ spatial biology platform providing whole-transcriptome coverage at single-cell sensitivity, enabling high-throughput spatial gene expression analysis on intact tissue.
  • Xenium In Situ High-plex in situ imaging platform for subcellular profiling of RNA targets from fresh frozen or FFPE tissues, integrating high-resolution imaging with onboard data analysis.
  • Visium Spatial NGS-based spatial gene expression platform providing whole-transcriptome spatial analysis at single-cell scale, with CytAssist-enabled workflow for FFPE and fresh frozen tissue samples.
  • Flex / Flex Apex Plate-based multiplexing single cell assay (Flex Apex) for profiling FFPE and fixed whole blood samples using Chromium Precision chemistry, with massive-throughput plate-based workflows.
  • Cell Ranger & Analysis Software Suite of free and cloud-based analysis pipelines, including Cell Ranger for data processing, Cloud Analysis for hosted analysis, and Loupe Browser for visualization, supporting 10x Genomics single cell and spatial data.

Quantifiable outcome

  • Up to 80% cell recovery efficiency with GEM-X chemistry
  • +4 more outcomes

Companies that use 10x Genomics, Inc.

Customer profile

Named customers10 records

Segments4 records

Ideal customer profiles5 records

10x Genomics, Inc. technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability6 records

Feature6 records

10x Genomics, Inc. partnerships and signals

Strategic signal

Partnerships

24 partnerships are on record, tiered strategic and core.

  • RochestrategicTechnology or Integration · 29 June 2026Collaboration supporting Roche's AXELIOS 1 next-generation sequencing platform launch, with 10x Genomics providing technology integration for data analysis capabilities. Positions 10x in sequencing market valued at USD 7.3 billion.
  • Cleveland CliniccoreStrategic or Co-development Partner · 17 June 2026Multi-year research collaboration to analyze advanced bladder cancer tumor samples using Flex Apex, Xenium, and Atera spatial biology platforms to identify biomarkers predicting patient response to antibody-drug conjugate treatments. Study will examine tumor samples from patients undergoing ADC and immunotherapy treatments, generating comprehensive multimodal datasets linking single cell and spatial profiles with clinical outcomes.
  • Proteintech GenomicscoreTechnology or Integration · 9 June 2026Acquisition of Proteintech Genomics, a division within Proteintech Group, expanding 10x's proteomics capabilities in single cell and spatial biology. The acquisition brings the Human Discovery Panel, the largest antibody-based single cell protein panel, designed to support integrated analysis of intracellular proteins, cell surface proteins, and transcriptomic profiles within sequencing-compatible workflows.
  • University of Pennsylvania (Carl June Lab)strategicTechnology or Integration · 18 April 2026Atera early access partner that generated data demonstrating platform's capabilities, including identification of rare immune cell populations and mapping of tumor microenvironments.
  • BioptimuscoreStrategic or Co-development Partner · 25 March 2026STELA (Spatial Tissue Embedding Learning Atlas) initiative anchored by 10x Genomics' Xenium platform, aiming to profile up to 100,000 patient tissue specimens across three continents (~20-fold increase over existing atlases). Serves as data backbone for M-Optimus multimodal world model of biology. Commercial expansion to Atera planned for 2027.
  • Broad Clinical LabscoreStrategic or Co-development Partner · 25 March 2026Strategic partner in STELA initiative contributing high-throughput laboratory workflows for generating harmonized multi-omics patient data across the 100,000-specimen atlas.
  • PerturbAIstrategicStrategic or Co-development Partner · 17 March 2026Collaboration producing world's largest in vivo CRISPR atlas with 8 million brain-wide cells using Perturb-seq technology. 10x Genomics provided technology for generating the largest known causal genomics resource in living tissue for drug discovery and AI model training.
  • Allen Institute for Brain SciencestrategicStrategic or Co-development Partner · 17 March 2026Collaboration partner in PerturbAI's 8M cell CRISPR atlas project, contributing to world's largest in vivo causal genomics resource for mouse brain research.
  • NVIDIAstrategicTechnology or Integration · 17 March 2026Technology partner providing accelerated computing infrastructure for PerturbAI's in vivo CRISPR atlas project and causal AI model development.
  • Stanford University School of MedicinestrategicStrategic or Co-development Partner · 26 February 2026Partner in CRI Discovery Engine initiative alongside 10x Genomics, Stanford University, Penn Medicine, and Memorial Sloan Kettering to standardize and pool cancer immunotherapy research for AI-driven breakthroughs.
  • University of Pennsylvania Perelman School of MedicinestrategicStrategic or Co-development Partner · 26 February 2026Partner in CRI Discovery Engine initiative to create shared data infrastructure for cancer immunotherapy research enabled by 10x platforms.
  • Memorial Sloan Kettering Cancer CenterstrategicStrategic or Co-development Partner · 26 February 2026Partner in CRI Discovery Engine initiative to standardize cancer immunotherapy research data infrastructure with 10x Genomics spatial and single cell platforms.
  • PharosAIcoreStrategic or Co-development Partner · 4 February 2026UK research consortium backed by £18.9 million government funding using Xenium spatial platform to build one of world's largest multimodal cancer datasets. Initiative will transform archived NHS cancer samples into high-resolution AI-ready datasets, initially focusing on breast cancer before expanding to lung and pancreatic cancer through 2027.
  • Dana-Farber Cancer InstitutecoreStrategic or Co-development Partner · 12 January 2026Multi-year collaboration analyzing tumor samples from hundreds of patients with major solid cancer types using Chromium Flex single cell assay and Xenium spatial platform. Research aims to identify biomarkers and develop clinical reporting framework for precision oncology treatments including ADCs, radioligand therapies, and bispecific antibodies.
  • Brigham and Women's HospitalcoreStrategic or Co-development Partner · 12 January 2026Collaboration analyzing peripheral blood samples from 1,000 patients with rheumatoid arthritis, systemic lupus erythematosus, and giant cell arteritis using Chromium Flex single-cell assay. Research aims to identify immune signatures associated with disease activity, flare, remission, and therapeutic response.
  • Cancer Research InstitutecoreStrategic or Co-development Partner · 12 January 2026AI-driven immuno-oncology initiative involving over 20,000 samples to build comprehensive dataset for future cancer treatments and vaccines using high-resolution biological data from 10x platforms.
  • CareDxcoreStrategic or Co-development Partner · 7 January 2026ImmuneScape multiomics research initiative leveraging Xenium spatial and Chromium Flex platforms to study transplant organ rejection at cellular resolution. Program will generate high-resolution maps of immune mechanisms underlying antibody-mediated rejection and microvascular inflammation to support future clinical diagnostic development.
  • AnthropicstrategicTechnology or Integration · 20 October 2025Integration of Anthropic's Claude for Life Sciences AI platform with 10x Genomics' single cell and spatial biology analysis platforms. Enables researchers to access, analyze, and interpret biological datasets through cloud-based interfaces for automated QC, gene/protein interaction analyses, and multi-step workflows.
  • Beckman Coulter Life SciencesstrategicTechnology or Integration · 1 January 2023Collaboration since 2023 to automate single cell gene expression workflows, enabling processing capacity increase to 96 samples per day vs 24 with manual methods, reducing hands-on time from over 5 hours to 1 hour.
  • Arc InstitutecoreStrategic or Co-development PartnerVirtual Cell Atlas initiative using Flex platform to generate 300M+ cell CRISPR perturbational dataset to fuel AI cell models that predict cellular responses and accelerate therapeutic target discovery.
  • Chan Zuckerberg InitiativecoreStrategic or Co-development PartnerBillion Cells Project using Chromium technology for landmark single cell dataset to deepen understanding of cellular behavior and gene function (1B cells).
  • OwkinstrategicStrategic or Co-development PartnerMOSAIC (Multi-Omics Spatial Atlas In Cancer) initiative using Visium and Flex technologies for massive pan-cancer spatial transcriptomics dataset (7,000 FFPE tissues) to enable AI-based therapeutic prediction modeling.
  • Xaira TherapeuticsstrategicStrategic or Co-development PartnerX-Atlas/Orion initiative using Universal 5' platform for largest publicly available Perturb-seq atlas targeting all human protein-coding genes for foundational model training (8M cells).
  • Ultima GenomicsstrategicTechnology or IntegrationPartnership combining 10x Genomics single cell and spatial sequencing quality with Ultima's ultra-low-cost sequencing capacity to unlock biological insights at large scales.

Scale indicators8 records

Recent moves6 records

Expansion highlights6 records

10x Genomics, Inc. competitors and assessment

Company assessment

Direct peers

  • Parse Biosciences: Direct competitor in single-cell RNA sequencing with an instrument-free, combinatorial barcoding chemistry (Evercode). Targets the same academic and translational single-cell market as Chromium with a different deployment model.
  • Standard BioTools (formerly Fluidigm): Direct peer in single-cell biology through mass cytometry (CyTOF/Hyperion imaging mass cytometry) and microfluidics-based single-cell workflows, competing for similar translational and immunology research customers.
  • Singleron Biotechnologies: Single-cell transcriptomics competitor offering the Microwell-seq-based Singleron Matrix and AccuraSCOPE platforms, particularly active in Asia-Pacific translational and clinical research markets overlapping with 10x.
  • Akoya Biosciences: Direct competitor in high-plex spatial biology through the CODEX/PhenoCycler platform, overlapping with Xenium in tissue imaging and multiplexed spatial phenotyping for translational research.
  • Bruker Spatial Biology (formerly NanoString Technologies): Direct competitor in spatial transcriptomics via the CosMx SMI platform and GeoMx Digital Spatial Profiler. Most head-to-head rival to 10x's Xenium and Atera in the in situ spatial biology market.

Broad incumbents

  • BD Biosciences (Becton Dickinson): Broad incumbent with the BD FACSDiscover S8 sorter combining spectral flow cytometry with imaging, plus cell sorting and single-cell genomics reagents. Competes for single-cell biology budgets across pharma and academic customers.
  • Pacific Biosciences: Long-read sequencing incumbent (Revio, Onso) increasingly bundled with single-cell workflows through partnerships with 10x-compatible kit providers; competes for translational genomics research budgets.
  • Illumina: Dominant next-generation sequencing incumbent whose platforms underpin 10x's NGS-based assays (Visium, Chromium); also develops connected-annotation and single-cell partnerships that compete with 10x-enabled workflows.
  • Bio-Rad Laboratories: Broad life science tools incumbent offering ddPCR, single-cell ATAC-seq (ATAC-Seq), and ZE5 cell analyzers, with overlapping presence in genomics and cell biology research labs that purchase 10x instruments.

Emerging players

  • Element Biosciences: Emerging sequencing platform (AVITI) pursuing cost-competitive short-read sequencing; competes for benchtop NGS budgets where 10x's Visium and Chromium workflows are deployed, with potential partnership overlap.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

10x Genomics, Inc. social profiles

Digital presence

10x Genomics, Inc. financial estimates

Financial estimate

Revenue estimate

Valuation estimate

10x Genomics, Inc. leadership team

Management profile

Number of profiles

Profiles5 records

10x Genomics, Inc. funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

10x Genomics, Inc. M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about 10x Genomics, Inc.

What does 10x Genomics, Inc. do?

10x Genomics develops and sells single cell and spatial multiomics platforms comprising capital instruments (Chromium, Atera, Xenium, Visium CytAssist), proprietary consumables and reagent kits, and analysis software (Cell Ranger, Cloud Analysis, Loupe Browser). Its products profile individual cells, detect rare populations, map spatial gene expression in tissues, and generate multiomic datasets for academic, translational, biopharmaceutical, and clinical research customers.

Is 10x Genomics, Inc. a public or private company?

10x Genomics, Inc. is a public company. It is classified as public and is currently operating.

When was 10x Genomics, Inc. founded?

10x Genomics, Inc. was founded in 2016. It employs 1,001 to 5,000 people.

Where is 10x Genomics, Inc. based?

10x Genomics, Inc. is headquartered in Pleasanton, United States, in the North America region.

How does 10x Genomics, Inc. make money?

Four revenue lines are on record. Instrument Sales are the primary driver. The others are consumables and Reagents, services and software and Cloud Analysis.

Who are 10x Genomics, Inc.'s main competitors?

Direct peers on record are Parse Biosciences, Standard BioTools (formerly Fluidigm), Singleron Biotechnologies, Akoya Biosciences and Bruker Spatial Biology (formerly NanoString Technologies). Broad incumbents are BD Biosciences (Becton Dickinson), Pacific Biosciences, Illumina and Bio-Rad Laboratories. Element Biosciences is listed as an emerging player.

Does 10x Genomics, Inc. have an API?

No public API is recorded for 10x Genomics, Inc..

What industry is 10x Genomics, Inc. in?

10x Genomics, Inc.'s product category is Single Cell and Spatial Biology Instruments. Its primary akta.pro industry code is HLAGAIAF, Molecular Biology & Genomics Instruments (PCR/qPCR, Sequencing, Microarrays), with a secondary code of HLAAAIAF, Single-Cell & Spatial Omics Discovery Platforms (target ID/validation, functional profiling). Its NAICS code is 334516 and its SIC code is 3826.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
American Banking and Market NewsResearch Analysts’ Recent Ratings Changes for 10x Genomics (TXG)Multiple research firms raised or set price targets for 10x Genomics, with Stifel, TD Cowen, Morgan Stanley, and others adjusting targets between $40 and $110. Insiders sold 179,333 shares over three months, and the company's product portfolio includes Chromium, Visium, and Xenium platforms.Stock TitanLunit Partners With 10x Genomics on AI PathologyLunit and 10x Genomics announced a collaboration to integrate Lunit SCOPE IO's AI pathology analysis with 10x's spatial molecular data for oncology biomarker research. The partnership will initially support studies on antibody-drug conjugates and immunotherapy response prediction, aiming to connect tissue morphology with molecular insights.AInvest10x Genomics Won a $4.8M Patent Case. That's Why the Stock Fell Anyway10x Genomics won a $4.8 million patent jury verdict against Parse Biosciences, but its stock fell over 5% despite the win. The award is a rounding error relative to 10x's $8 billion market value, and the market's re-rating is driven by its Atera spatial platform, which guides to mid-single-digit growth. The verdict's real value—permanent injunction—remains pending appeal.Law360Fed. Circ. Backs PTAB's Ax Of 10x Genomics Patent ClaimsThe Federal Circuit upheld the Patent Trial and Appeal Board's decision to invalidate specific patent claims held by 10x Genomics. The court affirmed that Parse Biosciences Inc.'s obviousness challenges against these nucleic acid analysis methods were valid. This legal ruling confirms the loss of patent protection for the specified technology.IPWatchdog.comFederal Circuit Upholds PTAB Obviousness Rulings Against Single Cell Sequencing PatentsThe U.S. Court of Appeals for the Federal Circuit affirmed Patent Trial and Appeal Board rulings that found three single-cell sequencing patents owned by 10x Genomics unpatentable as obvious. The court rejected all appeals raised by 10x Genomics, upholding decisions initiated by Parse Biosciences which argued that the patented methods combined prior-art elements in an obvious manner. This legal defeat invalidates key intellectual property rights held by 10x Genomics in the nucleic acid analysis sector.Investing.comCathie Wood’s ARK sells 10X Genomics stock, buys Perceptive Capital By Investing.comCathie Wood’s ARK ETFs executed a strategic rebalancing on August 14, 2026, selling 10,951 shares of 10X Genomics valued at $636,800 while acquiring 45,010 shares of Perceptive Capital Solutions for $522,566. The fund also increased positions in Cerus Corp and Schrödinger Inc, while reducing stakes in Twist Bioscience and Brera Holdings.Yahoo1 High-Flying Stock to Own for Decades and 2 We QuestionThe article discusses three stocks, highlighting 10x Genomics and Nabors Industries as underperformers while recommending Paymentus as a strong buy. 10x Genomics is facing market challenges with declining sales and negative returns on capital, while Nabors Industries struggles with high operating costs and poor cash flow margins. Paymentus, however, is seen as expanding its competitive advantage with a cloud-based platform for bill payments.The Motley Fool10x Genomics (TXG) Q2 2026 Earnings Call Transcript10x Genomics reported Q2 2026 revenue of $151.0 million, driven by strong demand for its new Atera spatial biology platform and growth in spatial consumables. The company raised its full-year revenue guidance to $610–$630 million while noting that instrument sales declined due to customers pausing purchases ahead of the Atera launch. Management highlighted significant strategic tailwinds from AI-driven research needs and announced the acquisition of Proteintech Genomics to enhance multi-omics capabilities.The Motley Fool10x Genomics (TXG) Q2 2026 Earnings Call Transcript10x Genomics reported Q2 2026 revenue of $151 million and raised its full-year guidance to $610–$630 million, driven by strong demand for its new Atera spatial biology platform which has already exceeded the annual shipment target. The company also acquired Proteintech Genomics to enhance multi-omics capabilities and highlighted AI-driven data generation as a structural growth tailwind, despite anticipating a modest sequential revenue decline in Q3 due to customer transition dynamics.Investing.com10x Genomics director John Stuelpnagel sells $1.15m in shares By Investing.comJohn Stuelpnagel, a director at 10x Genomics, sold $1.15 million worth of Class A Common Stock on August 11, 2026. The transaction involved the sale of 20,000 shares at prices ranging from approximately $57.58 to $58.73 per share. This divestment occurs as the company's stock trades near its 52-week high following a significant annual gain and recent earnings beats.